As part of a new Asia-Pacific (APAC) Life Sciences and Health Care webinar program designed both for companies with commercial interests in APAC and for companies based in the region, Hogan Lovells is hosting a special...more
China's National Medical Product Administration (“NMPA”), the administrative body responsible for regulating pharmaceuticals, medical devices and cosmetics in China, has recently launched a campaign to enforce the Regulation...more
The new Interpretation provides flesh to the bare bones of the provisions on punitive damages contained in China’s specific IP laws, which largely omit details on their specific application....more
On 11 November 2020, China's National People's Congress adopted an amended version of the Copyright Law, which will take effect on 1 June 2021. This is the first comprehensive revision of the Copyright Law since 2001, and the...more
China's new FIL and ambitious but controversial long-term strategies such as "Made in China 2025" mean potentially greater investment opportunities for international companies - particularly in high-tech manufacturing, life...more
6/5/2019
/ China ,
Foreign Direct Investment ,
Foreign Investment ,
Foreign Relations ,
Intellectual Property Protection ,
Investment Funds ,
Investment Opportunities ,
Investors ,
Multinationals ,
Technology Transfer Agreements ,
Trade Wars ,
US Trade Policies ,
Webinars
In a recent move involving both the Chinese legislature (the National People’s Congress) and the executive branch (the State Council), China has overhauled two of its most important pieces of legislation governing inbound...more
On 29 March 2018, the Chinese State Council released the External Transfer of Intellectual Property Rights Measures (for trial implementation) (the IPR Overseas Transfer Measures) providing for further governmental scrutiny...more